4D Molecular Therapeutics, Inc. (FDMT)
NASDAQ: FDMT · Real-Time Price · USD
3.330
-0.010 (-0.30%)
Apr 28, 2025, 4:00 PM EDT - Market closed
4D Molecular Therapeutics Stock Forecast
FDMT's stock price has decreased by -85.68% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 7 analysts with 12-month price forecasts for 4D Molecular Therapeutics stock have an average target of 30.29, with a low estimate of 6.00 and a high estimate of 40. The average target predicts an increase of 809.61% from the current stock price of 3.33.
Analyst Consensus: Buy
* Price targets were last updated on Mar 10, 2025.
Analyst Ratings
The average analyst rating for 4D Molecular Therapeutics stock from 8 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 5 | 5 | 4 | 4 | 3 |
| Buy | 4 | 4 | 4 | 4 | 4 | 3 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 11 | 11 | 10 | 10 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| B of A Securities | B of A Securities | Strong Buy Maintains $42 → $40 | Strong Buy | Maintains | $42 → $40 | +1,101.20% | Mar 10, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $30 → $28 | Strong Buy | Maintains | $30 → $28 | +740.84% | Mar 4, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $39 → $35 | Buy | Maintains | $39 → $35 | +951.05% | Mar 3, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $36 | Strong Buy | Reiterates | $36 | +981.08% | Mar 3, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $39 → $30 | Strong Buy | Maintains | $39 → $30 | +800.90% | Feb 11, 2025 |
Financial Forecast
Revenue This Year
4.95M
from 37.00K
Increased by 13,270.27%
Revenue Next Year
4.94M
from 4.95M
Decreased by -0.18%
EPS This Year
-3.64
from -2.98
EPS Next Year
-3.93
from -3.64
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 21.0M | 21.0M | 21.0M | ||
| Avg | 4.9M | 4.9M | 4.7M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 56,656.8% | 324.5% | 325.3% | ||
| Avg | 13,270.3% | -0.2% | -4.9% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -3.14 | -2.98 | -1.63 | ||
| Avg | -3.64 | -3.93 | -3.95 | ||
| Low | -4.61 | -5.40 | -6.28 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.